Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.4M 2.24M 2.06M 3.86M 264M 3.92M 26.28M 10.3M 132M 10.41M 10.19M 437M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.59M 8.02M 7.36M 13.83M 945M 14.05M 94.06M 36.87M 473M 37.27M 36.46M 1.57B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 70 01/03/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.22%+31.00%+70.51% 54.32B
+2.72%+0.88%-15.84%-12.03% 22.91B
-1.09%+29.18%+17.83%+496.18% 28.73B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+8.41%+45.17%-21.02% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+3.58%-3.39%+43.38%+166.75% 13.12B
Average +3.84%+7.42%+51.29%+198.59% 28.15B
Weighted average by Cap. +4.19%+9.95%+47.56%+164.93%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.96 0.1 0.69 0.27 3.49 0.27 0.27 11.53 0.14 0.12 0.11 0.1 0.19 12.89 0.19 1.28 0.5 6.46 0.51 0.5 21.35
Net income -3.1M -2.69M -2.51M -2.3M -4.33M -296M -4.39M -29.42M -11.53M -148M -11.66M -11.4M -490M -18.47M -15.99M -14.92M -13.7M -25.75M -1.76B -26.14M -175M -68.62M -881M -69.36M -67.86M -2.91B
Net Debt 7.1M 6.14M 5.73M 5.26M 9.89M 675M 10.04M 67.23M 26.35M 338M 26.64M 26.06M 1.12B 7.15M 6.19M 5.78M 5.3M 9.97M 681M 10.12M 67.78M 26.57M 341M 26.86M 26.27M 1.13B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-